Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Gaining Momentum in the Treatment of Eye Disease

Avalanche is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Using a next generation gene therapy platform, the Ocular BioFactory™, the Company is developing products designed to provide long-term benefit or a functional cure by inducing a sustained expression of a therapeutic protein with a one-time administration in the eye.

Read More



Avalanche Biotechnologies Phase 2a and Phase 1 36-month Follow-up Data Conference Call and Webcast
Monday, June 15
5 p.m. ET/2 p.m. PT

Avalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration

June 15, 2015

MENLO PARK, Calif., June 15, 2015 – Avalanche Biotechnologies, Inc. (Nasdaq: AAVL) today announced that its Phase 2a clinical study for AVA-101 met its 12-month primary endpoint, based on ophthalmic and systemic safety, demonstrating that AVA-101 was well tolerated with a favorable safety profile in subjects with wet age-related macular degeneration (wet AMD).

Read More

Read All Avalanche News